Ignite Creation Date:
2024-05-06 @ 1:56 PM
Last Modification Date:
2024-10-26 @ 1:22 PM
Study NCT ID:
NCT04167917
Status:
RECRUITING
Last Update Posted:
2023-08-08
First Post:
2019-11-12
Brief Title:
NTX-301 in MDSAML
Sponsor:
University of Alabama at Birmingham
Organization:
University of Alabama at Birmingham
Study Overview
Official Title:
A Phase 1 Study of NTX-301 an Oral DNMT1 Inhibitor in Patients With MDS and AML
Status:
RECRUITING
Status Verified Date:
2024-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
NTX-301 is a DNMT1 inhibitor The drug is an oral drug with preclinical data that has shown preclinical anti-leukemic efficacy This is the first clinical trial using NTX-301 in patients with myeloid malignancies
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None